Severe and sometimes fatal hepatitis reported; hepatitis usually develops during the first 3 months of therapy but may develop after many months.
Risk of developing hepatitis is age related. Approximate case rates by age are: <1 per 1000 in individuals <20 years of age; 3 per 1000 in individuals 20–34 years of age; 12 per 1000 in individuals 35–49 years of age; 23 per 1000 in individuals 50–64 years of age; 8 per 1000 in individuals >65 years of age.
Risk of hepatitis is increased by daily consumption of alcohol, chronic liver disease, and use of illicit injection drugs.
There may be an increased risk of fatal hepatitis in women, particularly black and Hispanic women. Risk also may be increased during the postpartum period.
Precise data on fatality rate for isoniazid-related hepatitis not available. There were 8 deaths among 174 cases of hepatitis in a US Public Health Service Surveillance Study that included 13,838 individuals.
Monitor and interview patients at monthly intervals. In addition, determine AST and ALT concentrations at baseline and periodically (monthly or more frequently as needed) in individuals ≥35 years of age and in individuals at increased risk of hepatitis.
Increases in serum transaminase concentrations occur in 10–20% of patients; these increases usually occur during the first few months of therapy but can occur at any time. Enzyme concentrations usually return to pretreatment values despite continued isoniazid therapy, but progressive liver dysfunction occurs in some cases.
Consider discontinuing isoniazid if liver function abnormalities are >3–5 times ULN.
Liver function tests are not a substitute for monthly clinical evaluations or for prompt assessment of signs or symptoms of adverse reactions that may occur between regularly scheduled evaluations.
Patients should be advised to immediately report prodromal symptoms of hepatitis to their clinician. (See Advice to Patients.)
Discontinue immediately if symptoms or signs suggestive of hepatic damage are detected; continued isoniazid use has been reported to cause a more severe form of liver damage.
Patients who have signs or symptoms of isoniazid-associated hepatic damage should be treated using alternative antituberculosis agents. If use of isoniazid is considered necessary, the drug should be restarted only after symptoms and laboratory abnormalities have cleared. In this situation, isoniazid should be restarted in very small dosages and gradually increased; discontinue immediately if there is any indication of recurrent liver involvement.
Use of isoniazid for treatment of latent tuberculosis infection (LTBI) should be deferred in patients with acute hepatic disease.
Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents.
First-line agent for treatment of all forms of active TB caused by Mycobacterium tuberculosis known or presumed to be susceptible to the drug. Essential component of multiple-drug regimens used for the initial intensive treatment phase and the continuation treatment phase.
Fixed-combination preparation containing rifampin and isoniazid (Rifamate®) is used for treatment of pulmonary TB. Isoniazid and rifampin both are used in the initial intensive treatment phase and the continuation treatment phase, but manufacturer states that Rifamate® is not recommended for initial therapy, and the fixed-combination preparation should be used only after the patient has been treated with the individual components and efficacy of these drugs has been established.
Fixed combination preparation containing rifampin, isoniazid, and pyrazinamide (Rifater®) is used for treatment of pulmonary TB; designated an orphan drug by US FDA for this use. Used only in the initial intensive treatment phase since pyrazinamide is not usually indicated for the continuation phase.
For initial treatment of active TB caused by drug-susceptible M. tuberculosis, recommended multiple-drug regimens consist of an initial intensive phase (2 months) and a continuation phase (4 or 7 months). Although the usual duration of treatment for drug-susceptible pulmonary and extrapulmonary TB (except disseminated infections and TB meningitis) is 6–9 months, ATS, CDC, and IDSA state that completion of treatment is determined more accurately by the total number of doses and should not be based solely on the duration of therapy. A longer duration of treatment (e.g., 12–24 months) usually is necessary for infections caused by drug-resistant M. tuberculosis.
Patients with treatment failure or drug-resistant M. tuberculosis, including multidrug-resistant (MDR) TB (resistant to both isoniazid and rifampin) or extensively drug-resistant (XDR) TB (resistant to both isoniazid and rifampin and also resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial such as capreomycin, kanamycin, or amikacin), should be referred to or managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.
Latent Tuberculosis Infection
Treatment of latent tuberculosis infection (LTBI).
LTBI is asymptomatic infection with M. tuberculosis; usually defined as a positive tuberculin skin test (TST) or Quantiferon®-TB gold test (QFT-G) with no evidence of active (clinical) TB. LTBI is treated to decrease the risk of progression to active TB.
Regimen of choice for treatment of LTBI is isoniazid monotherapy, unless the patient has been in contact with an individual with drug-resistant TB. Rifampin monotherapy is the preferred alternative and is especially useful in adults, adolescents, or children who have been exposed to isoniazid-resistant M. tuberculosis and those who cannot tolerate isoniazid. Rifabutin is used in those who cannot receive rifampin because of intolerance or because they are receiving other drugs that have clinically important interactions with rifampin (e.g., HIV patients receiving certain antiretroviral agents).
Treatment of LTBI in patients who have been exposed to a source case with drug-resistant TB, including MDR TB or XDR TB, should be managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.
Prior to initiating treatment of LTBI, clinical (active) TB must be excluded using appropriate testing (e.g., radiographs).
Mycobacterium avium Complex (MAC) Infections
Has been used for treatment of M. avium complex (MAC) infections† in conjunction with other antimycobacterials.
Although a multiple-drug regimen of isoniazid, rifampin, and ethambutol (with streptomycin during the initial 3–6 months) has been used for treatment of MAC pulmonary infections, isoniazid is not included in current ATS, CDC, NIH, or IDSA recommendations for treatment of MAC infections, including macrolide-resistant MAC.
Treatment of MAC infections is complicated and should be directed by clinicians familiar with mycobacterial diseases; consultation with a specialist is particularly important when the patient cannot tolerate first-line drugs or when the infection has not responded to prior therapy or is caused by macrolide-resistant MAC.
Mycobacterium kansasii and Other Mycobacterial Infections
Treatment of M. kansasii infections in conjunction with other antimycobacterials. ATS and IDSA recommend a regimen of isoniazid, rifampin, and ethambutol for treatment of pulmonary or disseminated infections caused by rifampin-susceptible M. kansasii. If rifampin-resistant M. kansasii are involved, ATS and IDSA recommend a 3-drug regimen based on results of in vitro susceptibility, including clarithromycin (or azithromycin), moxifloxacin, ethambutol, sulfamethoxazole, or streptomycin.
Treatment of M. xenopi† infections in conjunction with other antimycobacterials. Optimum regimens not established; in vivo response may not correlate with in vitro susceptibility. ATS and IDSA state that a regimen of clarithromycin, rifampin, and ethambutol has been used, although the rate of relapse is high. A regimen of isoniazid, rifampin (or rifabutin), ethambutol, and clarithromycin (without or without streptomycin during initial treatment) also has been suggested.
Dosage and Administration
Administration
Administer orally. May be given IM when oral therapy is not feasible.
Used in conjunction with other antimycobacterial agents for treatment of active (clinical) TB. Used alone for treatment of LTBI.
Fixed-combination preparations (Rifamate® containing rifampin and isoniazid; Rifater® containing rifampin, isoniazid, and pyrazinamide) can be used for treatment of active TB infection to reduce the pill burden and ensure compliance, especially when directly observed (supervised) therapy (DOT) cannot be used. A fixed-combination preparation should be used only when all drugs in the preparation are indicated.
Oral Administration
Administer orally in the fasting state. Do not administer with food. (See Food under Pharmacokinetics.)
Rifamate® or Rifater®: Administer orally with a full glass of water 1 hour before or 2 hours after a meal.
Dosage
Oral and IM dosage is the same.
Dosage of Rifamate ® is expressed as number of capsules; dosage of Rifater® is expressed as number of tablets.
Concomitant administration of pyridoxine (vitamin B6) is recommended in adults, adolescents, and pediatric patients who are malnourished (including those on meat- or milk-deficient diets) and in those predisposed to neuropathy (e.g., those with alcoholism, diabetes, HIV infection, seizure disorders, or renal failure). Administration of pyridoxine also is recommended in pregnant or nursing women; breast-feeding infants do not require pyridoxine unless they are receiving isoniazid. (See Nervous System Effects under Cautions.)
Pediatric Patients
Tuberculosis
Treatment of Active (Clinical) Tuberculosis
Oral
Children: 10–15 mg/kg (up to 300 mg) once daily or 20–40 mg/kg (up to 900 mg) 2 or 3 times weekly recommended by the manufacturers.
Children <15 years of age or weighing ≤40 kg: 10–15 mg/kg (up to 300 mg) once daily or 20–30 mg/kg (up to 900 mg) twice weekly recommended by ATS, CDC, IDSA, AAP, and others.
Adolescents ≥15 years of age: 5 mg/kg (up to 300 mg) once daily or 15 mg/kg (up to 900 mg) 1–3 times weekly recommended by ATS, CDC, and IDSA.
Rifater® in adolescents ≥15 years of age: 4 tablets once daily in those weighing ≤44 kg, 5 tablets once daily in those weighing 45–54 kg, or 6 tablets once daily in those weighing ≥55 kg. Used only in the initial phase of treatment.
IM
Children: 10–15 mg/kg (up to 300 mg) once daily or 20–40 mg/kg (up to 900 mg) 2 or 3 times weekly.
Latent Tuberculosis Infection (LTBI)
Oral
Infants, children, and adolescents: 10–15 mg/kg (up to 300 mg) once daily or 20–30 mg/kg (up to 900 mg) 2 or 3 times weekly recommended by manufacturers, ATS, CDC, IDSA, AAP, USPHS, and others.
The usual duration of isoniazid monotherapy for treatment of LTBI in children is 9 months, especially in HIV-infected individuals. A 6-month regimen is not recommended for children.
ATS and CDC recommend that completion of therapy for LTBI be based on total number of administered doses rather duration of therapy alone. When the 9-month once-daily isoniazid regimen is used, at least 270 doses should be administered within 12 months. Ideally, patients should receive the drug on a regular dosing schedule until completed; in practice, some doses may be missed requiring the course to be lengthened. If the regimen is resumed after an interruption of ≥2 months, a medical examination is indicated to rule out active TB.
IM
Children: 10 mg/kg (up to 300 mg) once daily or 20–30 mg/kg (up to 900 mg) twice weekly.
Adults
Tuberculosis
Treatment of Active (Clinical) Tuberculosis
Oral
5 mg/kg (up to 300 mg) once daily or 15 mg/kg (up to 900 mg) 1–3 times weekly recommended by manufacturers, ATS, CDC, IDSA, and others.
Rifamate®: 2 capsules once daily.
Rifater®: 4 tablets once daily in adults weighing ≤44 kg, 5 tablets once daily in adults weighing 45–54 kg, or 6 tablets once daily in adults weighing ≥55 kg. Used in the initial phase of treatment.
IM
5 mg/kg (up to 300 mg) once daily or 15 mg/kg (up to 900 mg) 2 or 3 times weekly.
Latent Tuberculosis Infection (LTBI)
Oral
5 mg/kg (up to 300 mg) once daily or 15 mg/kg (up to 900 mg) twice weekly recommended by ATS, CDC, IDSA, USPHS, and others.
Adults weighing >30 kg: 300 mg once daily recommended by manufacturers.
The usual duration of isoniazid monotherapy for treatment of LTBI is 9 months. A 6-month regimen may be used in some adults, but a 9-month regimen should be used in immunocompromised or HIV-infected individuals or those with fibrotic lesions on chest radiographs.
ATS and CDC recommend that completion of therapy for LTBI be based on total number of administered doses rather duration of therapy alone. When the 9-month once-daily isoniazid regimen is used, at least 270 doses should be administered within 12 months. When the 6-month once-daily isoniazid regimen is used, at least 180 doses should be administered within 9 months. Ideally, patients should receive the drug on a regular dosing schedule until completed; in practice, some doses may be missed requiring the course to be lengthened. If the regimen is resumed after an interruption of ≥2 months, a medical examination is indicated to rule out active TB.
IM
Adults weighing >30 kg: 300 mg once daily or 20–30 mg/kg (up to 900 mg) twice weekly.
Mycobacterium kansasii Infections
Treatment of Pulmonary or Disseminated Infections Caused by Rifampin-susceptible M. kansasii
Oral
5 mg/kg (up to 300 mg) daily in conjunction with ethambutol (15 mg/kg once daily) and rifampin (10 mg/kg [up to 600 mg] daily), and pyridoxine (50 mg daily) recommended by ATS and IDSA.†
Continue until patient has been culture negative on treatment for 1 year. A longer duration may be needed in HIV-infected individuals with disseminated infections.†
Prescribing Limits
Pediatric Patients
Active (Clinical) Tuberculosis or Latent Tuberculosis Infection (LTBI)
Oral
Maximum 300 mg per dose in once-daily regimens or 900 mg per dose in 2- or 3-times weekly regimens.
When used in conjunction with rifampin, isoniazid dosage >10 mg/kg daily may increase the incidence of hepatotoxicity.
Adults
Active (Clinical) Tuberculosis or Latent Tuberculosis Infection (LTBI)
Oral
Maximum 300 mg per dose in once-daily regimens or 900 mg per dose in 2- or 3-times weekly regimens.
Special Populations
Hepatic Impairment
Risk of drug accumulation may be increased, but no specific dosage recommendations available. (See Hepatic Impairment under Cautions.)
Renal Impairment
No dosage adjustment needed in patients with renal impairment, including end-stage renal disease; supplemental doses not necessary in hemodialysis patients. (See Renal Impairment under Cautions.)
Severe and sometimes fatal hepatitis reported. (See Boxed Warning.)
Sensitivity Reactions
Hypersensitivity Reactions
Hypersensitivity reactions, including fever, skin eruptions (morbilliform, maculopapular, purpuric, or exfoliative), lymphadenopathy, or vasculitis reported.
At first sign of hypersensitivity, discontinue all drugs and evaluate patient. If isoniazid must be reinstituted, the drug should be restarted only after symptoms have cleared. Isoniazid should be restarted in very small dosages and gradually increased; discontinue immediately if there is any indication of recurrent hypersensitivity reaction.
General Precautions
Nervous System Effects
Peripheral neuritis (usually preceded by paresthesia of the feet and hands) reported. Appears to be dose-related and is uncommon with recommended dosages. Occurs most frequently in those who are malnourished or predisposed to neuritis (e.g., alcoholics, diabetics, HIV-infected, renal failure) and in those who are slow inactivators of isoniazid (see Elimination under Pharmacokinetics).
Neuropathy may be prevented or relieved by pyridoxine (vitamin B6). ATS, CDC, IDSA, AAP, and USPHS recommend pyridoxine supplementation in adults, adolescents, and children at increased risk of neuropathy (e.g., those with malnutrition, alcoholism, diabetes, HIV infection, seizure disorders, or renal failure), pregnant or breast-feeding women, and in breast-feeding infants receiving isoniazid. Multivitamin preparations contain variable amounts of pyridoxine and usually will not provide adequate supplementation in these patients. Some experts recommend a pyridoxine dosage of 10–25 mg daily during isoniazid therapy; higher dosage may be recommended in HIV-infected adults.
Carefully monitor patients with peripheral neuropathy or conditions that predispose to neuropathy.
Patient Monitoring
Because of risk of isoniazid-associated hepatitis, closely monitor and interview patients once monthly. Determine serum transaminase concentrations prior to and periodically during treatment in those at increased risk, including daily users of alcohol, patients >35 years of age, those with chronic liver disease, those who use illicit injection drugs, and women (particularly during the postpartum period and in those who belong to minority groups). (See Boxed Warning.)
Carefully monitor patients who are daily users of alcohol, those who are >35 years of age, those receiving long-term concomitant therapy, those who previously discontinued isoniazid, those who use illicit injection drugs, those with a history of peripheral neuropathy or conditions predisposing to neuropathy, those with active chronic liver disease or severe renal dysfunction, women who are pregnant or in the postpartum period, women who belong to minority groups, and HIV-infected individuals.
Perform periodic ophthalmologic examinations if visual symptoms occur during isoniazid therapy.
Use of Fixed Combinations
When the fixed-combination preparations (Rifamate® containing rifampin and isoniazid or Rifater® containing rifampin, isoniazid, and pyrazinamide) are used, observe the usual precautions and contraindications associated with all drugs in the preparation. Use these preparations only when all drugs contained in the fixed combination are indicated.
Precautions Related to Treatment of Tuberculosis
Should not be used alone for treatment of active TB; must be used in conjunction with other antituberculosis agents.
Clinical specimens for microscopic examination and mycobacterial cultures and in vitro susceptibility testing should be obtained prior to initiation of antituberculosis therapy and periodically during treatment to monitor therapeutic response. The antituberculosis regimen should be modified as needed. Patients with positive cultures after 4 months of treatment should be considered to have failed treatment (usually as the result of noncompliance or drug-resistant TB).
Compliance with the full course of antituberculosis therapy and all drugs included in the multiple-drug regimen is critical. Missed doses increase the risk of treatment failure and increase the risk that M. tuberculosis will develop resistance to the antituberculosis regimen.
To ensure compliance, ATS, CDC, IDSA, and AAP recommend that directly observed (supervised) therapy (DOT) be used for treatment of active (clinical) TB and for treatment of LTBI whenever possible, especially when intermittent regimens are used, when the patient is immunocompromised or infected with HIV, or when drug-resistant M. tuberculosis is involved.
Specific Populations
Pregnancy
Category C.
A regimen of isoniazid, rifampin, and ethambutol is recommended by ATS, CDC, IDSA, and AAP for treatment of active (clinical) TB in pregnant women. Consider that the risk of fatal isoniazid-associated hepatitis may be increased in women, especially during the postpartum period. Carefully monitor when used during pregnancy and the postpartum period (especially in women belonging to minority groups).
Treatment for LTBI generally should be deferred until after delivery to avoid risk to the fetus.
If isoniazid is used during pregnancy, consider concomitant use of pyridoxine. (See Nervous System Effects under Cautions.) Neonates born to women who received isoniazid during pregnancy should be carefully observed for evidence of adverse effects.
Lactation
Distributed into milk, but manufacturers state that breast-feeding should not be discouraged. Consider use of pyridoxine in breast-feeding woman; her breast-fed infant does not require pyridoxine unless also receiving isoniazid. (See Nervous System Effects under Cautions.)
Isoniazid concentrations in breast milk are too low to be considered therapeutic for the infant.
Pediatric Use
Used in infants and children for treatment of active (clinical) TB and treatment of LTBI.
Rifamate®: Safety and efficacy not established in pediatric patients.
Rifater®: Safety and efficacy not established in children <15 years of age; the ratio of rifampin and isoniazid in this preparation may not be appropriate for this age group.
Infants, children, and adolescents who experience paresthesias while receiving isoniazid and those who are malnourished (including those on meat- or milk-deficient diets) or have conditions that predispose to neuropathy (e.g., HIV infection, renal failure) should receive pyridoxine supplementation during isoniazid therapy. Breast-feeding infants receiving isoniazid also should receive pyridoxine supplementation. Routine administration of pyridoxine in other pediatric patients is not recommended.
Hepatic Impairment
Risk of drug accumulation and isoniazid-associated hepatitis may be increased. (See Boxed Warning.)
Carefully monitor patients with chronic liver disease. Contraindicated in patients with acute liver disease.
Renal Impairment
Carefully monitor patients with severe renal impairment.
Common Adverse Effects
Nervous system effects (peripheral neuropathy), hepatic effects (elevated transaminase concentrations).
Reduced rate of acetylation of isoniazid (especially in rapid acetylators) reported with some aminosalicylic acid preparations; appears to be dose related
Interaction not studied using commercially available aminosalicylic acid delayed-release granules (Paser®); the lower serum concentrations produced by the delayed-release preparation should result in a reduced effect on acetylation of isoniazid
Increased carbamazepine concentrations; symptoms of carbamazepine toxicity reported
Increased risk of isoniazid-induced hepatotoxicity
Determine carbamazepine concentrations prior to and during isoniazid therapy; closely monitor for carbamazepine toxicity and adjust carbamazepine dosage as needed
Increased theophylline concentrations; slight decrease in elimination of isoniazid
Monitor theophylline concentrations; adjust theophylline dosage as needed
Valproate
Increased plasma valproate concentrations
Monitor plasma valproate concentrations; adjust dosage of valproate as needed
Pharmacokinetics
Absorption
Bioavailability
Readily absorbed from GI tract; peak plasma concentrations achieved within 1–2 hours.
Readily absorbed from IM injection sites.
Food
Food reduces oral bioavailability.
Plasma Concentrations
Plasma concentrations in rapid isoniazid inactivators are 20–50% of those in slow isoniazid inactivators.
Distribution
Extent
Distributed into all body tissues and fluids, including pleural fluid, ascitic fluid, saliva, and sputum.
CSF concentrations are 90–100% of concurrent plasma concentrations.
Crosses the placenta.
Distributed into milk in concentrations comparable to those in plasma.
Plasma Protein Binding
Not substantially bound.
Elimination
Metabolism
Inactivated in the liver, mainly by acetylation and dehydrazination. The rate of acetylation is genetically determined, and usually is constant for each person. Rate of acetylation does not have a clinically important effect on efficacy, but slow acetylators may have higher blood concentrations of the drug and may be at increased risk of toxic reactions.
Slow inactivation is an autosomal recessive trait and results from a relative deficiency of the hepatic enzyme N-acetyltransferase. Approximately 50% of whites and blacks are slow inactivators of isoniazid; the majority of native Alaskans and Asians (Japanese, Chinese) are rapid inactivators.
Elimination Route
Eliminated principally in urine (75–96%) as unchanged drug and metabolites. Small amounts excreted in saliva, sputum, and feces.
Half-life may be prolonged in patients with impaired hepatic function or severe renal impairment.
Stability
Storage
Oral
Oral Solution
15–30°C in tight, light-resistant container.
Capsules
Rifamate®: Avoid excessive heat; store in a dry place in tightly closed container.
Tablets
20–25°C; protect from light and moisture.
Rifater®: 15–30°C. Protect from excessive humidity.
Parenteral
Injection
20–25°C; protect from light. May crystallize at low temperatures. If this occurs, warm the vial at room temperature to dissolve the crystals before use.
Actions
Bactericidal in action.
Interferes with metabolism of bacterial proteins, nucleic acids, carbohydrates, and lipids. Appears to inhibit mycolic acid synthesis in susceptible bacteria which results in loss of acid-fastness and disruption of the bacterial cell wall.
A highly specific antibacterial agent; active only against Mycobacterium. Active in vitro and in vivo against M. tuberculosis, M. bovis, and some strains of M. kansasii. M. marinum is resistant.
Natural and acquired resistance to isoniazid observed in vitro and in vivo in M. tuberculosis.
M. tuberculosis resistant to both isoniazid and rifampin (MDR TB) occurs. There also have been recent reports of extensively drug-resistant (XDR) TB in various parts of the world, including the US. XDR TB is caused by M. tuberculosis resistant to rifampin and isoniazid (multiple-drug resistant strains) that also are resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial (capreomycin, kanamycin, amikacin).
Advice to Patients
Advise patients that poor compliance with antituberculosis regimens can result in treatment failure and development of drug-resistant TB, which can be life-threatening and lead to other serious health risks.
Importance of completing full course of therapy; importance of not missing any doses.
Advise patients to take isoniazid in the fasting state.
Importance of informing clinicians if signs or symptoms of liver damage or other adverse effects occur, including loss of appetite, malaise, persistent fatigue, nausea, vomiting, dark urine, icterus, rash, persistent paresthesias of the hands and feet, weakness or fever lasting >3 days, and/or abdominal tenderness (especially right upper quadrant discomfort).
Advise patient to avoid histamine-containing food (e.g., skipjack, tuna, tropical fish) and tyramine-containing food and beverages (e.g., cheese, red wine) during isoniazid therapy.
Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Isoniazid
Routes
Dosage Forms
Strengths
Brand Names
Manufacturer
Bulk
Powder*
Oral
Solution
50 mg/5 mL*
Isoniazid Syrup (with sorbitol 70%)
Carolina Medical
Tablets
100 mg*
Isoniazid Tablets
Barr, VersaPharm, West-Ward
300 mg*
Isoniazid Tablets
Barr, VersaPharm, West-Ward
Parenteral
Injection
100 mg/mL*
Isoniazid Injection® (with chlorobutanol 0.25%)
Sandoz
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Isoniazid Combinations
Routes
Dosage Forms
Strengths
Brand Names
Manufacturer
Oral
Capsules
150 mg with Rifampin 300 mg*
Rifamate®
Sanofi-Aventis
Rifampin and Isoniazid Capsules
VersaPharm
Tablets
50 mg with Pyrazinamide 300 mg and Rifampin 120 mg
Rifater® (with povidone and propylene glycol)
Sanofi-Aventis
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 09/2009. For the most current and up-to-date pricing information, please visit www.drugstore.com. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
† Use is not currently included in the labeling approved by the US Food and Drug Administration.
Remember, keep this and all other medicines out of the reach of children,
never share your medicines with others, and use this medication only for the indication prescribed.
Sign up with Facebook
